The VEGFR2 inhibitor ramucirumab has been approved by the FDA for the treatment of advanced gastric cancer and gastroesophageal junction cancer in 2014 either as monotherapy or in combination with paclitaxel (Fuchs et al., 2014; Wilke et al., 2014). This evidence concerns the gene KDR and gastric cancer.